| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10011228 | HBV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30005072 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30005073 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30001457 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30011160 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30014456 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30011161 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30005074 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30001458 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
| TVIS30011162 | HIV | ENSG00000171608.18 | protein_coding | PIK3CD | Yes | No | 5293 | O00329 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PIK3CD |
|---|---|
| DrugBank ID | DB14989 |
| Drug Name | Umbralisib |
| Target ID | BE0002406 |
| UniProt ID | O00329 |
| Regulation Type | inhibitor |
| PubMed IDs | 29475723; 30936084; 31558467; 32634240 |
| Citations | Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20.@@Authors unspecified: Umbralisib: Treatment for a Rare Lymphoma? Cancer Discov. 2019 Jun;9(6):OF5. doi: 10.1158/2159-8290.CD-NB2019-045. Epub 2019 Apr 1.@@Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S: Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. doi: 10.1182/blood.2019002118.@@Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, Pinilla-Ibarz J: The dual PI3Kdelta/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084. doi: 10.1182/bloodadvances.2020001800. |
| Groups | Approved; Investigational; Withdrawn |
| Direct Classification | |
| SMILES | CC(C)OC1=C(F)C=C(C=C1)C1=NN([C@@H](C)C2=C(C3=CC=CC(F)=C3)C(=O)C3=CC(F)=CC=C3O2)C2=C1C(N)=NC=N2 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3948730 |
